Cann GroupASX:CAN -25.00% Net Margin % is 583.48% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, Cann Group ranks better than 99.27% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cann Group's Net Income for the
six
months ended in Dec. 2025 was A$26.38 Mil. Cann Group's Revenue for the
six
months ended in Dec. 2025 was A$4.52 Mil. Therefore, Cann Group's net margin for the quarter that ended in Dec. 2025 was 583.48%.
The historical rank and industry rank for Cann Group's Net Margin % or its related term are showing as below:
ASX:CAN'
s Net Margin % Range Over the Past 10 Years
Min: -2617.77 Med: -439.09 Max: 157.49
Current: 157.49
ASX:CAN's Net Margin % is ranked better than 99.27% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs ASX:CAN: 157.49
Cann Group (ASX:CAN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cann Group Net Margin % Related Terms
Cann Group Net Margin % Historical Data
* Premium members only.
The historical data trend for Cann Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cann Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cann Group (ASX:CAN) has a Net Margin % of 583.48% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Cann Group and its competitors. According to the industry distribution chart, Cann Group ranks #7 out of 956 companies in the Drug Manufacturers industry, placing it in the top 0.7%.
Is Cann Group's Net Margin % too high?
Cann Group's current Net Margin % is 583.48%. The Drug Manufacturers industry median Net Margin % is 5.56. Cann Group's value of 583.48% is 10394.2% above this industry median. Based on the distribution chart, Cann Group ranks #7 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #7 out of 956 companies for Net Margin %. This places Cann Group in the top 1% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Cann Group's value of 583.48% is 10394.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current Net Margin % of 583.48% is 10394.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cann Group and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current Net Margin % is 583.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 85% below its estimated fair value. The current Net Margin % is 583.48% and 10394.2% above the Drug Manufacturers industry median of 5.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current Net Margin % is 583.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 